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Abstract
An emerging treatment for Parkinson’s disease (PD) is cell replacement therapy. 
Authentic midbrain dopaminergic (mDA) neuronal precursors can be differentiated from 
human embryonic stem cells (hESCs) and human induced pluripotent stem cells (iPSCs). 
These laboratory- generated mDA cells have been demonstrated to mature into functional 
dopaminergic neurons upon transplantation into preclinical models of PD. However, 
clinical trials with human fetal mesenchephalic cells have shown that cell replacement 
grafts in PD are susceptible to Lewy body formation suggesting host- to- graft transfer of 
α- synuclein pathology. Here, we have used CRISPR/Cas9n technology to delete the en-
dogenous SNCA gene, encoding for α- synuclein, in a clinical- grade hESC line to gener-
ate SNCA+/− and SNCA−/− cell lines. These hESC lines were first differentiated into 
mDA neurons, and then challenged with recombinant α- synuclein preformed fibrils 
(PFFs) to seed the formation for Lewy- like pathology as measured by phosphorylation of 
serine- 129 of α- synuclein (pS129- αSyn). Wild- type neurons were fully susceptible to the 
formation of protein aggregates positive for pS129- αSyn, while SNCA+/− and SNCA−/− 
neurons exhibited significant resistance to the formation of this pathological mark. This 
work demonstrates that reducing or completely removing SNCA alleles by CRISPR/
Cas9n- mediated gene editing confers a measure of resistance to Lewy pathology.
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1 |  INTRODUCTION
Parkinson’s disease (PD) is a common neurological disorder 
that is caused by the loss or dysfunction of specific neuro-
nal cell types. The dopaminergic neurons of the substantia 
nigra pars compacta that innervate the dorsal striatum are 
significantly affected in this condition. The degeneration of 
the nigrostriatal dopaminergic pathway is largely responsible 
for the motor symptoms of PD.
An experimental therapy for PD is transplantation of 
fetal ventral mesencephalic cells into the striatum (Lindvall 
et al., 1988, 1990, 1994). Although some patients experi-
enced long- term alleviation of motor symptoms (Li et al., 
2016; Ma et al., 2010), a significant proportion suffered 
from graft- induced dyskinesias (Hagell et al., 2002; Piccini 
et al., 2005), which was attributed to serotonergic hyperin-
nervation from the graft (Politis et al., 2010). Furthermore, 
most grafts older than 10 years acquired Lewy body pa-
thology suggesting that host- to- graft spread of disease 
may be occurring (Kordower, Chu, Hauser, Freeman, & 
Olanow, 2008; Li et al., 2008; Mendez et al., 2008). The 
burden of Lewy bodies in the graft correlated with a de-
crease in the symptomatic benefit to the patient (Chu & 
Kordower, 2010). These clinical observations highlight the 
need for cell therapies that are resistant to the formation of 
Lewy bodies, which are predominantly composed of the 
protein α- synuclein (Spillantini et al., 1997). Such disease- 
resistant cells will be particularly important for patients 
with young- onset Parkinson’s or genetic forms of the con-
dition with substantial α- synuclein burden, such as SNCA 
multiplications (Farrer et al., 2004) and GBA mutation 
carriers (Neumann et al., 2009).
In cell culture and animal models of PD, synucleinopathy 
can be initiated by inoculation with preformed fibrils (PFFs) of 
recombinant α- synuclein protein. In primary rodent neurons, 
molecular pathology is observed by monitoring the phosphor-
ylation of α- synuclein at position serine- 129. This is a prom-
inent posttranslational event that is found in Lewy bodies, 
and is an early event during the aggregation of α- synuclein 
(Fujiwara et al., 2002). If neurons lack endogenous expression 
of α- synuclein they are not susceptible to α- synuclein PFF seed-
ing (Volpicelli- Daley et al., 2011), and it has been described 
that neurons with low endogenous expression of α- synuclein 
are spared in PD (Braak, Ghebremedhin, Rüb, Bratzke, & Del 
Tredici, 2004). Furthermore, when Snca−/− mice were stereo-
tactically injected with α- synuclein PFFs they exhibited no signs 
of synucleinopathy or neurodegeneration unlike their wild- type 
counterparts (Luk et al., 2012).
The differentiation of human embryonic stem cells 
(hESCs) and induced pluripotent stem cells (iPSCs) into 
midbrain dopaminergic (mDA) neurons is now well under-
stood and described (Kirkeby et al., 2017; Kriks et al., 2011), 
and the route to clinical trials for hESC/iPSC- derived mDA 
cell therapy for Parkinson’s has been mapped out (Barker, 
Parmar, Studer, & Takahashi, 2017). However, these grafts 
will express wild- type levels of α- synuclein protein making 
them susceptible to synucleinopathy with a similar kinetics 
to fetal mesencephalic grafts. Here, we show that deleting 
alleles of the SNCA gene in hESCs and iPSCs reduces or 
eliminates α- synuclein expression from mDA neurons and 
confers resistance to α- synuclein PFF induced formation of 
Lewy- like pathology. This work sets out a strategy to produce 
disease- resistant mDA grafts for Parkinson’s that will last the 
life time of the individual, and will be particularly important 
for patients with an aggressive synucleinopathy.
2 |  MATERIALS AND METHODS
2.1 | hESC and iPSC culture
Approval for the use of hESCs used in this study was granted 
by the MRC Steering Committee for the UK Stem Cell Bank 
and for the Use of Stem Cell Lines (ref, SCSC13- 19). RC17 
hESCs (~passages 25- 30) and AST18 iPSCs were maintained 
in self- renewing conditions on Laminin- 521 (L521, 5 μg/ml, 
Biolamina) coated 6- well plates (Corning), and fed daily with 
StemMACS iPS- Brew XF (iPS- B, Miltenyi Biotec). Every 2 
or 3 days, once the hESCs reached 70%–90% confluency, the 
cells were passaged as clumps with EDTA (0.5 mM, Thermo 
Fisher Scientific) at a split ratio of 1:3 to 1:8. See Supporting 
Information Table S1 for all catalogue numbers.
2.2 | Cloning of gRNA plasmids
For each gRNA, a 100 bp double- stranded DNA fragment 
was made by PCR of a pair of partially complementary 
single- stranded DNA, of which the complementary sequence 
was the gRNA (Mali et al., 2013). The fragment was then 
cloned into BbsI- HF (NEB) digested pSpCas9n- 2A- Puro 
plasmid (PX462, Addgene) (Ran et al., 2013) by Gibson as-
sembly and transfected into Stbl3 competent E. coli (Thermo 
Fisher Scientific). The PX462 plasmid was obtained under a 
standard Addgene MTA (Order 152516) with the Provider 






2.3 | SNCA knockout with CRISPR/Cas9n
RC17 hESCs or AST18 iPSCs (8 × 105 cells) were transfected 
with 1 μg of each of the 4 gRNA plasmids and GFPiPuroR 
(a GFP indicator plasmid) using Amaxa™ Human Stem 
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Cell Nucleofector™ Kit 1 (Lonza) and programme B- 016 on 
Nucleofector® II (Lonza). 24 hr after transfection, puromycin 
(0.5 μg/ml, Sigma) selection (16 hr) was applied for cells on 
Matrigel (Thermo Fisher Scientific) or 1.0 μg/ml puromycin for 
cells on L521 (5 μg/ml). Clones were picked 8–14 days after 
transfection and expanded on L521- coated 96- well plates.
2.4 | PCR genotyping
DNA was extracted from hESC clones using 1 hr incubation 
at 98°C in Solution I (25 mM NaOH and 0.2 mM EDTA) 
followed by termination with Solution II (40 mM Tris- HCl). 
Three PCR reactions flanking the targeted region were per-
formed using Q5® High- Fidelity DNA Polymerase (NEB) 
with primers to produce products of 449 bp, 943 bp, and 
1,927 bp.
PCR primer sequences (5′–3′):
449 bp Forward: cacactttggagggtttctc
449 bp Reverse: ctggaaaagcaaacagtcgc
943 bp Forward: cagcttccatgcttctaactc
943 bp Reverse: ctttatacacatcacaggggc
1,927 bp Forward: ccacaagggctgagagat
1,927 bp Reverse: tggtcatcctccacctga
PCR products were electrophoresed in 2% agarose 
(Thermo Fisher Scientific) gels with Quick- Load® 100 bp 
DNA ladder (NEB) or 1 kb DNA ladder (NEB).
2.5 | Western blotting
Cells were lysed with RIPA Lysis Buffer System (Santa Cruz) 
according to manufacturer’s instructions. Following quantifi-
cation of protein concentration using the BCA assay (Thermo 
Fisher Scientific), 15 μg of protein was incubated with 
NuPAGE™ LDS loading dye (1:4, Thermo Fisher Scientific) 
and NuPAGE™ Sample Reducing Agent (1:10, Thermo 
Fisher Scientific) at 70°C for 10 min and then loaded onto 
NuPAGE™ 4%–12% Bis- Tris Protein Gel (Thermo Fisher 
Scientific) with SeeBlue™ Plus2 ladder (Thermo Fisher 
Scientific). The protein was electrophoresed and transferred 
onto Amersham™ Protran™ Premium 0.45 μm NC nitrocel-
lulose membrane (Amersham). The membrane was fixed 
with 0.4% paraformaldehyde (PFA, Fisher) for 30 min and 
blocked with 10% blocking- grade blocker (BioRad) in 0.05% 
TBS- N. Mouse anti- α- synuclein primary antibody (BD, 
1:1,000) was added in 5% blocking- grade blocker in 0.05% 
TBS- N and rocked at 4°C overnight. Following secondary 
antibody (HRP conjugated anti- mouse IgG, Promega) incu-
bation, Pierce™ ECL Western Blotting Substrate (Thermo 
Fisher Scientific) was applied before image acquisition. After 
antibodies were removed with Restore™ PLUS Western Blot 
Stripping Buffer (Thermo Fisher Scientific), the membrane 
was blocked and reblotted with anti- β- actin antibody (HRP 
conjugate, Abcam) in 5% blocking- grade blocker in 0.05% 
TBS- N. Pierce™ ECL Western Blotting Substrate was ap-
plied prior to image acquisition.
2.6 | TOPO- cloning and DNA sequencing
PCR products of putative SNCA knockout clones were pu-
rified with Wizard® SV Gel and PCR Clean- Up System 
(Promega), incubated with Taq DNA polymerase at 72°C for 
10 min, and inserted into pCR™4- TOPO® vector (TOPO® 
TA Cloning® Kit for Sequencing, Thermo Fisher Scientific) 
according to manufacturer’s instructions. The plasmids were 
respectively transfected into DH5α competent E. coli (NEB) 
according to manufacturer’s instructions. Carbenicillin 
(Fisher) was used at 100 μg/ml in LB/agar plates for selec-
tion of transformed cells. The next day, clones were picked 
into liquid LB- containing 100 μg/ml carbenicillin. After 
overnight incubation, plasmids were isolated with QIAprep 
Spin Miniprep Kit (QIAGEN). The purified plasmids were 
digested with EcoRI (NEB) and electrophoresed on 1% aga-
rose gel. The plasmids of potential SNCA knockout clones 
(using T7 primer) and the purified PCR product of the poten-
tial α- synuclein homozygous knockout clones were sent for 
Sanger sequencing at the MRC PPU DNA Sequencing and 
Services (Dundee).
2.7 | Off- target analysis
The top two potential off- target sites for 5G1 and 3G1 
gRNAs were identified using the CRISPR design webtool 
(http://crispr.mit.edu/).
Potential off- target sites:
5G1 off-target #1: tgtattccagtacaccacac (chr15:+46664956)
5G1 off-target #2: tgagttcctctccaccacac (chr10:+80560295)
3G1 off-target #1: gccatggctgtattcaagaa (chr9:+93313553)
3G1 off-target #2: gccctgggtgcattcatgaa (ch22:+25774724)
PCR primer sequences and product sizes for off-target 
analysis (5′–3′):
5G1 OffTgt1F: ccagacttcacaaccaccca, R: caggatcaagtggg 
gtgtgg (370 bp)
5G1 OffTgt2F: tggcagcaggtttcctactc, R: gctcttggttgtactggcct 
(527 bp)
3G1 OffTgt1F: gcttgggcaacacaatgaga, R: acctgtctatccgtctgccc 
(532 bp)
3G1 OffTgt2F: catgctctgcctcaaccaga, R: cagagaggcaggcat 
gtgaa (311 bp)
PCR products were generated and subjected to a T7E1 assay 
to determine if any of the potential off- target sites sustained a 
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deletion or insert. Briefly, PCR products were dissociated and 
re- annealed before addition of T7E1 (10U, NEB) in NEBuffer™ 
2 (NEB) and incubated at 37°C for 20 min. Reaction products 
were electrophoresed in 2% agarose (Thermo Fisher Scientific) 
gels with Quick- Load® 100 bp DNA ladder (NEB).
2.8 | Midbrain dopaminergic neuronal 
differentiation
For differentiation, hESCs were seeded at a density of 40,000 
cells/cm2 onto Laminin- 111 (L111, 5 μg/ml, Biolamina) coated 
plates according to an adapted published protocol (Kirkeby 
et al., 2017). Cells were differentiated from day 0 to day 4 in 
neural induction medium (NIM) which was made up of 50% 
DMEM/F12 (Thermo Fisher Scientific) + 50% Neurobasal 
Media (Thermo Fisher Scientific) + B27 supplement (without 
Vitamin A, 1:50, Thermo Fisher Scientific) + N2 supplement 
(1:100, Thermo Fisher Scientific) + l- Glutamine (2 mM, 
Thermo Fisher Scientific). Y27632 (Y2, 10 μM, Tocris) was 
present in medium from day 0 to day 2. From day 0 to day 
9, SB431542 (SB, 10 μM, Millipore), LDN- 193189 (LDN, 
100 ng/ml, Miltenyi Biotec), Shh- C24II (SHH, 600 ng/ml, 
R&D Systems) and CHIR99021 (CHIR, 1.3 μM, Miltenyi 
Biotec) were added. From day 4 to day 11, medium was changed 
to neural patterning medium (NPM) which consisted of 50% 
DMEM/F12 + 50% Neurobasal Media + B27 supplement 
(1:100) + N2 supplement (1:200) + l- Glutamine (2 mM). 
From day 9 to day 16, FGF8b (100 ng/ml, R&D Systems) and 
heparin (1 μg/ml, Sigma) were added to the medium. On day 
11, cells were lifted with Accutase (Sigma) and replated to 
L111-coated 48- well plates at a density of 800,000 cells/cm2. 
From day 11, cells were fed with neural differentiation me-
dium (NDM) which was Neurobasal Media + B27 supplement 
(1:50) + l- Glutamine (2 mM) and supplemented with ascorbic 
acid (AA, 0.2 mM, Sigma), brain- derived neurotrophic factor 
(BDNF, 20 ng/ml, Peprotech) and glial cell line- derived neuro-
trophic factor (GDNF, 10 ng/ml, Peprotech), as well as FGF8b 
and heparin. On day 16, cells were lifted with Accutase and 
replated in L111-coated 48- well plates at a density of 800,000 
cells/cm2. From day 16, cells were cultured in NDM supple-
mented with dibutyryl cyclic AMP (dcAMP, 0.5 mM, Sigma) 
and DAPT (1 μM, Tocris) in addition to BDNF, GDNF, and 
AA. Around day 25, cells were lifted with Accutase and re- 
plated onto poly- ornithine (0.0015%, Sigma) + L111-coated 
8- well glass bottom plates (ibidi) at 25,000 cells/cm2. Cells 
were fed on days 2, 4, 7, 9, 11, 14, 16, every 2–3 days after day 
16, and weekly after re- plated onto glass bottom plates.
2.9 | Gene expression analysis by RT- qPCR
Total RNA was isolated and DNaseI- treated from self- renewing 
hESCs and day 44 mDA neurons with the MasterPure™ 
Complete DNA and RNA Purification Kit (Epicentre) 
following the manufacturer’s instructions. cDNA was syn-
thesized from 500 ng of total RNA using the SuperScript™ 
IV Reverse Transcriptase (Thermo Fisher Scientific). qPCR 
was performed using the Roche LightCycler® 480 System 
with the Universal Probe Library (UPL) (Roche). The Roche 
UPL Assay design centre was used to design intron- spanning 
primers with a specific UPL probe for each gene (TBP 
F- gaacatcatggatcagaacaaca R- atagggattccgggagtcat Probe 87; 
NANOG F- tctccaacatcctgaacctca R- ttgctattcttcggccagtt Probe 87; 
OCT4 F- tgccgtgaaactggagaag, R- gcttggcaaattgttcgagt Probe 78; 
DAT F- agactgcccgaagtgtgc, R- gcagtttcccgttacaccaa Probe 14; 
NURR1 F- atttcctcgaaaacgcctgt, R- catactgcgcctgaacacaa Probe 
41; SOX6 F- gcttctggactcagcccttta, R- ggccctttagcctttggtta Probe 
50; VMAT2 F- cgggattctgcatcatgttt, R- tggcaatcagcaggaagg Probe 
67). Reactions (10 μl) containing cDNA, primers, UPL Probe, 
LightCycler® 480 Probes Master mix (Roche) and PCR water were 
performed in 386- well plates as described in the manufacturer’s 
instructions. The data were normalized to levels of TATA-binding 
protein (TBP) and the data of technical replicates were plotted.
2.10 | Immunostaining
Cells were fixed with 4% PFA and blocked with 2% donkey 
serum (Sigma) in PBS- T (0.1% Triton X- 100 (Fisher) in PBS 
(Thermo Fisher Scientific)). Primary antibodies used include 
tyrosine hydroxylase (1:1,000, rabbit, Millipore), FOXA2 
(1:100, goat, Santa Cruz), α-synuclein (1:250, mouse IgG2a, 
Abcam), α-synuclein (1:250, mouse IgG1, BD), phosphoser-
ine‐129 α-synuclein (pS129- αSyn, 1:1,000, rabbit, Abcam) 
and β- III tubulin (1:1,000, mouse IgG2b, Abcam). Secondary 
antibodies including donkey anti- rabbit IgG Alexa Fluor- 488 
(Thermo Fisher Scientific), donkey anti- goat IgG Alexa 
Fluor- 568 (Thermo Fisher Scientific), donkey anti- mouse 
IgG Alexa Fluor- 647 (Abcam), goat anti- mouse IgG2a Alexa 
Fluor- 488 (Thermo Fisher Scientific), goat anti- mouse IgG1 
Alexa Fluor- 488 (Thermo Fisher Scientific), goat anti- mouse 
IgG2b Alexa Fluor- 647 (Thermo Fisher Scientific) were used 
at 1:1,000, while DAPI (Thermo Fisher Scientific) was used at 
1:10,000. Images were acquired on the Axio Observer (Zeiss) or 
the Eclipse Ti-E (Nikon) microscope.
2.11 | Flow cytometry
For flow cytometry, cells were harvested with Accutase and 
washed with NDM. Cells were re- suspended with flow cy-
tometry buffer, which consisted of DPBS (Sigma) + 2% fetal 
calf serum (Thermo Fisher Scientific), and stained with rat 
anti- CORIN antibody (R&D Systems, 1:200). Cells were 
washed with flow cytometry buffer and stained with donkey 
anti- rat IgG Alexa Fluor- 488 (Thermo Fisher Scientific). 
Flow cytometry was performed on BD FACS Calibur (BD 
Biosciences) and analysed on the FlowJo software program 
(FlowJo, LLC).
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2.12 | Production of α- synuclein preformed 
fibrils (PFFs)
Human SNCA cDNA was cloned into a plasmid for 
mammalian expression, pMKC451, under the control of 
a CMV promoter. This plasmid (1 mg) was transfected 
into Expi293 cells (>97% viability, 2,500 million cells) 
grown in Expi293 Expression Medium (A1435101, 
Gibco) using Expi293fectamine (1956760, Gibco) and 
Opti- MEM (11058021, Gibco), according to manufac-
turer’s instructions. The culture was incubated at 37°C, 
120 rpm, 8% CO2 (Kuhner Shaker X) and after 17 hr 
Enhancers 1 and 2 (1956760, Gibco) were added as spec-
ified. The culture was harvested 4 days after transfec-
tion (typical viability 40%) by centrifugation (90 min, 
5,000 g, JS4.2 rotor in J6- MI Beckman) and filter steri-
lised through a 0.22 μm filter (Millipak Gammagold, 
Millipore) using a Sartobran P 0.45 + 0.22 μm prefilter 
(Sartorius Stedim).
Supernatant was diluted with an equal volume 20 mM 
Tris (T1503, Sigma)/HCl (20252.335, VWR Chemicals) pH 
8.0 made up in FlowFusor pyrogen free water (FBP7205, 
Fresenius Kabi) and was passed over a 2 × 5 ml HiTrap 
Q FF column (17- 5156- 01, GE Healthcare). Bound pro-
tein was eluted with a gradient to 0.4M NaCl (S/3160/60, 
Fisher Chemical) in 20 mM Tris/HCl over 20 column vol-
umes. Fractions with α- synuclein were pooled, concen-
trated using a Centriprep 10K, 10,000 NMWL spin filter 
(4305, Millipore) and buffer exchanged into 20 mM Tris/
HCl pH8.0 using a HiPrep 26/10 desalting column (GE 
Healthcare). Anion exchange chromatography was re-
peated using a MonoQ 10/100GL column (GE Healthcare) 
and fractions with α- synuclein were pooled, concentrated 
and purified over a HiLoad 26/600 Superdex 75 column 
(GE Healthcare) equilibrated in PBS (P5368, Sigma) 
made up in FlowFusor pyrogen free water (FBP7205, 
Fresenius Kabi). Analysis throughout the purifications 
was performed by 4%–12% NuPage Bis/Tris gel electro-
phoresis using SeeBlue Plus2 prestained molecular weight 
marker. The final pool was concentrated, filter sterilized 
(0.22 μm Millex GV, Millipore) to 5–10 mg/ml protein and 
stored at −80°C in BioPur Safe- Lock tubes (0030121.589, 
Eppendorf).
Protein was analysed by HuPage gel electrophoresis 
and a single protein species was observed (Supporting 
Information Figure S5A), and electrospray mass spec-
trometry (ESI+) gave a deconvoluted mw of 14502 Da 
(mw calc. 14501 Da for N- acetylated species). Size ex-
clusion chromatography with multi- angle static light 
scattering (SEC- MALS) (data not shown), JC- 1 fluores-
cence (Lee et al., 2009), and attenuated total reflectance 
Fourier- transform infrared (ATR- FTIR) spectrometry 
analysis were used to confirm that the recombinant human 
α- synuclein was monomeric (Supporting Information 
Figure S5B,C). Endotoxin level was measured by 
Limulus Amebocyte Lysate test (PTS20F, Charles River 
Laboratories). The protein was not phosphorylated at po-
sition serine- 129 as determined by the pS129-αSyn anti-
body (Abcam).
The PFFs were prepared by shaking the purified human 
α- synuclein monomer (7–10 mg/ml, 0.50 ml) in 1.5- ml 
BioPur Eppendorf vials at 1,200 rpm, 37°C for 10 days, 
using a VorTemp56 incubator (Labnet). The resulting ma-
terial was analysed using JC- 1 (T3168, Molecular Probes) 
fluorescence (Lee et al., 2009) on a Varian Cary Eclipse 
fluorimeter, 100 g ultracentrifugation (Beckman Optima 
TLX with a TLA- 120.1 rotor) sedimentation to measure re-
sidual monomer by NuPage gel electrophoresis and ATR- 
FTIR spectrometry analysis (Tensor 27, Bruker) (Kaylor 
et al., 2005). Material with a main JC- 1 fluorescence ab-
sorbance at 540 nm (Supporting Information Figure S5B), 
<5% monomer as judged by NuPage electrophoresis of 
the ultracentrifugation supernatant and an ATR- FTIR 
absorption between 1,625 and 1,630 cm−1 (Supporting 
Information Figure S5C) was sonicated for 4 × 10 seconds 
at 2.5 mg/ml PBS in 1.5- ml BioPur Eppendorf vial on ice 
using a Soniprep sonicator (MSE). The protein solution 
was aliquoted and frozen on dry ice and stored at −80°C in 
BioPur Eppendorf vials.
2.13 | PFF seeding and pS129- αSyn 
quantification
On day 44 of mDA differentiation, neurons were exposed 
to α- synuclein PFFs or monomers (5 μg/ml) by replac-
ing consumed media with feeding media containing the 
α- synuclein protein. Half of the consumed media were 
replaced weekly until 5 weeks after seeding. After im-
munostaining with pS129- αSyn and β- III tubulin, neu-
rons were imaged with Axio Observer (Zeiss) or Eclipse 
Ti- E (Nikon) and deconvoluted with Huygens (Scientific 
Volume Imaging). Images were processed with Fiji 
(National Institutes of Health): Z- project images of the 
two channels were created after setting brightness and 
contrast, followed by converting to binary images. In 
order to only quantify pS129- αSyn structures within β- III 
tubulin- positive neurons, a Boolean “AND” function of 
the two binary images was performed on Fiji. The area of 
pS129- αSyn immunostaining divided by the total area of 
β- III tubulin was used for quantification. Statistical analy-
sis was performed in PrismGraphPad software to compare 
experimental conditions. A two- tailed, unpaired nonpara-
metric analysis was performed using the Mann–Whitney 
U test.
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3 |  RESULTS
3.1 | CRISPR- mediated deletion of SNCA in 
hESCs
A series of guideRNAs (gRNAs) flanking exon 2, the first 
coding exon, of human SNCA were designed using the 
Zhang Lab CRISPR DESIGN webtool (http://crispr.mit.
edu). The oligonucleotides encoding for the top 2 pairs of 
gRNAs at the 5′ end of SNCA exon 2 and the top 2 pairs 
of gRNAs at the 3′ end of SNCA exon 2 were cloned in 
the pSpCas9n- 2A- Puro plasmid (Ran et al., 2013) and 
tested for deletion efficiency in HEK 293 cells (data not 
shown). We employed the nickase mutant of Cas9, Cas9- 
D10A (Cas9n), to avoid off- target double- strand breaks in 
the cells (Ran et al., 2013). Based on cutting efficiency in 
HEK 293 cells, we decided upon 5G1 and 3G1 gRNAs to 
target the 5′ end of SNCA exon 2, and 5G4 and 3G4 gRNAs 
to target the 3′ end (Figure 1a). We designed a PCR screen-
ing strategy to detect hESC clones with a complete dele-
tion of exon 2. We used RC17 hESCs as the parental line, 
since it has all the regulatory paperwork in place to be used 
as a cell therapy in clinical trials (De Sousa et al., 2016). 
Here, hESCs were electroporated with four gRNA Cas9n 
plasmids and clones selected in puromycin. After replica 
plating of the clonal hESC lines, genomic DNA was iso-
lated from 51 clones and analysed for exon 2 deletion by 
PCR (Figure 1a). Nine putative SNCA−/− clones and four 
putative SNCA+/− clones were identified by this method. 
The wild- type PCR band is expected to be ~450 bp and the 
knock- out SNCA alleles were typically between 400 bp and 
200 bp in size for this initial PCR screening (Figure 1b). A 
collection of putative knock- out clones were investigated 
further with long- range PCR genotyping strategies to de-
termine if larger deletions could be detected (Figure 1c,d). 
This revealed that clone M1- 4 harboured two unique 
knock- out alleles, only the first of which could be detected 
by the original PCR genotyping method. Clone L5- 3 ap-
peared to have only a single deletion allele, and no wild- 
type alleles (Figure 1c,d). The PCR products of four hESC 
clones were TOPO- cloned and sent for Sanger sequenc-
ing to determine the precise deletion events (Supporting 
Information Figures S1–S3). Clones 4- 4 and L5- 4 were pu-
tative SNCA+/− cell lines. Clone 4- 4 had one intact allele, 
and a 210- bp deletion in the second allele removing most of 
exon 2 including the ATG start site. Clone L5- 4 harboured 
a 175- bp deletion in one allele removing the ATG, and a 
12- bp insertion in the 5′ UTR and 28- bp deletion in intron 
2 of the second allele (Figure 1e, Supporting Information 
Figure S2). Clones M1- 4 and L5- 3 were putative SNCA−/− 
cell lines. Clone M1- 4 had a 214- bp deletion in one al-
lele, and a 428- bp deletion in the second allele, both of 
which remove exon 2 and the ATG start codon (Figure 1e, 
Supporting Information Figure S3). Clone L5- 3 harboured 
a 250- bp deletion removing exon 2 and an absence of any 
wild- type allele. All three PCR genotyping reactions only 
detected a single allele in Clone L5- 3 suggesting the dele-
tions are nearly identical on both alleles, or that the second 
allele has a deletion beyond the detection of the ~1.9 kb 
PCR reaction (Figure 1d). We investigated the four most 
likely off- target cleavage sites in the genome using a T7 
endonuclease I (T7E1) assay. We did not observe any off- 
target cleavage at these sites as anticipated from using 
the Cas9n system (Supporting Information Figure S4). 
We then checked α- synuclein protein expression in these 
clones and others by western blotting of undifferentiated 
hESC lysates. Clones M1- 4, L5- 3, and other clones were 
confirmed to lack any detectable α- synuclein expression, 
while putative SNCA+/− clones, 4- 4 and L5- 4 had reduced 
expression (Figure 1f). This suggested that the small inser-
tion on the 5′UTR and 28- bp deletion in intron 2 of Clone 
L5- 4 did not affect α- synuclein expression.
3.2 | Normal midbrain dopaminergic 
differentiation of SNCA targeted hESCs
Reduction or deletion of the SNCA gene may affect differ-
entiation efficiency into mDA neurons. In order to address 
this question, we differentiated two SNCA+/− hESC lines and 
two SNCA−/− lines, as well as the wild- type RC17 parental 
hESC line, using a modified version of an established mDA 
neuronal protocol (Figure 2a; Nolbrant, Heuer, Parmar, & 
Kirkeby, 2017). FACS analysis for the floor plate marker, 
CORIN, at day 16 of differentiation showed that all cell 
lines produced a highly pure population of floor plate cells 
regardless of SNCA genotype (Figure 2b). Gene expres-
sion analysis at day 44 of differentiation showed a down- 
regulation of the pluripotent markers OCT4 and NANOG 
in all genotypes of cell line, and an up- regulation of the 
dopaminergic markers NURR1, SOX6, DAT, and VMAT2 
in all cell lines regardless of SNCA genotype (Figure 2c). 
This suggests deletion of the SNCA gene does not have 
a major effect on the differentiation of hESCs into mDA 
neurons. Immunostaining for the pan- neuronal marker, β- 
III tubulin, the dopaminergic enzyme tyrosine hydroxylase 
(TH), and the midbrain marker, FOXA2, further confirmed 
there were no gross differences in the differentiation poten-
tial of SNCA−/− hESCs to produce dopaminergic neurons 
(Figure 3a,b). Wild- type and both SNCA+/− hESC lines 
exhibited nuclear and cytoplasmic α- synuclein expression, 
while mDA neurons differentiated from both SNCA−/− cell 
lines lacked this expression (Figure 4), in agreement with 
the western blotting data. The localization of α- synuclein 
is not synaptic in these neuronal cultures at day 44 because 
they were not sufficiently mature yet. This is in agreement 
with the observation that α- synuclein is not redistributed 
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FIGURE 1 Generation of SNCA+/− and SNCA−/− human embryonic stem cell (hESC) clones and characterization their CRISPR deletions.  
(a) A schematic view of SNCA exon 2 with the location of CRISPR targeting gRNAs and PCR screening primers indicated. (b) PCR screening 
results of a subset (16) of the clonal hESC lines analysed on 3 separate gels. The expected wild- type (WT) band size is 449 bp. (c, d) Long- 
range PCR of four putative SNCA+/− or SNCA−/− clones for larger regions around the targeted sites: expected WT band sizes are: (c) 943 bp and 
(d) 1,927 bp. (e) Schematic summary of sequencing results for two SNCA+/− clones (L5- 4 and 4- 4) and two SNCA−/− clones (M1- 4 and L5- 3). 
(f) Western blotting results for α- synuclein (α- Syn) protein for twelve putative SNCA+/− or SNCA−/− clones analysed on two separate gels. 
Eight α- Syn- null clones were confirmed, and two putative SNCA+/− clones (L5- 4 and 4- 4) had a reduced level of α- Syn expression. β- actin was 
blotted as a loading control
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from the cell body to synapses until 18 weeks of gestation 
(Galvin, Schuck, Lee, & Trojanowski, 2001).
3.3 | α- Synuclein- null mDA neurons are 
resistant to acquiring Lewy- like pathology
We induced synucleinopathy in human neurons by using 
an established α- synuclein preformed fibrils (PFFs) model 
(Volpicelli- Daley et al., 2011). Human α- synuclein protein 
was produced using a HEK 293 mammalian expression sys-
tem. Monomeric protein was agitated for 10 days to form 
fibrils that were quality controlled by JC- 1 fluorescence 
(Lee et al., 2009), and Fourier- transform infrared (FTIR) 
spectrometry analysis (Kaylor et al., 2005) (Supporting 
Information Figure S5). The fibrillar protein was then soni-
cated on ice to produce PFFs. Recombinant α- synuclein 
PFFs, or monomers, were added to the culture medium of day 
44 mDA neurons at a concentration of 5 μg/ml. After 5 weeks 
F I G U R E  2  Midbrain dopaminergic (mDA) neuronal differentiation of hESCs is unaffected by deletion of the SNCA gene. (a) Floor plate 
mDA differentiation protocol. (b) Corin flow cytometry of day 16 mDA progenitors differentiated from SNCA+/−, SNCA−/− or WT hESCs: Corin 
(red) and no primary antibody control (blue). (c) RT- qPCR of hESCs and day 44 mDA neurons for pluripotency markers, OCT4 and NANOG, 
and dopaminergic markers, NURR1, DAT, SOX6, and VMAT2. Gene expression levels were normalized to Tata- binding protein (TBP), plotted as 
mean ± standard deviation of technical replicates
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F I G U R E  3  Deletion of SNCA does not affect expression of tyrosine hydroxylase (TH) or FOXA2 in mDA neurons. (a) Immunostaining 
of day 44 mDA neurons differentiated from SNCA+/−, SNCA−/− or WT hESCs; TH (green)/β- III tubulin (red). (b) Day 44 mDA neurons 
immunostained for FOXA2 (white) and quantified as a percentage of total cells (DAPI, blue)
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of additional culture and maturation of neurons, the cells 
were immunostained for β- III tubulin and phosphoSer- 129- 
α- synuclein (pS129- αSyn) (Figure 5a), a posttranslational 
modification that occurs in Lewy bodies and is a reliable 
biomarker of aggregated α- synuclein (Fujiwara et al., 2002). 
mDA neurons exposed to α- synuclein PFFs exhibited nu-
merous pS129- αSyn structures within neurons after 5 weeks, 
while α- synuclein monomers were unable to induce the for-
mation of these structures (Figure 5b). To quantify the extent 
of Lewy- like molecular pathology in neurons, the immu-
nostaining of pS129- αSyn and β- III tubulin were converted 
to binary images and the percentage of β- III tubulin- positive 
space (i.e. neurons) occupied by pS129- αSyn signal was cal-
culated (Figure 5b).
F I G U R E  4  α- Synuclein protein is absent from SNCA−/− mDA neurons and reduced in SNCA+/− clones. (a) Immunostaining of day 44 mDA 
neurons differentiated from SNCA+/−, SNCA−/− or WT hESCs; total α- synuclein (green)/β- III tubulin (red). (b) Immunostaining of day 44 mDA 
neurons differentiated from SNCA−/− or WT hESCs: stained with total α- synuclein (green)/TH (red)/β- III tubulin (white)
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We then compared wild- type, SNCA+/−, and SNCA−/− 
mDA neurons for their susceptibility to form phosphorylated 
α- synuclein structures in response to pathology- inducing 
PFFs in the same time- frame (5 weeks). Wild- type mDA 
neurons exhibited extensive pS129- αSyn structures due to 
α- synuclein PFF seeding (Figure 6a). Heterozygous SNCA+/− 
mDA neurons exhibited much less pS129- αSyn immunos-
taining, but a small number of neurons showed punctate 
pS129- αSyn- positive structures along axons (Figure 6a). 
Knock- out SNCA−/− mDA neurons did not possess any 
pS129- αSyn- positive structures that followed axonal tracks 
or co- localised with β- III tubulin- positive neuronal cell bod-
ies (Figure 6a). Quantification of the pS129- αSyn structures 
with respect to the area of β- III tubulin- positive neurons 
showed that SNCA+/− and SNCA−/− mDA neurons were sig-
nificantly less susceptible to forming Lewy- like structures 
than wild- type neurons when challenged with α- synuclein 
PFFs (Figure 6b). Control monomeric α- synuclein at the 
same concentration or vehicle, PBS, were unable to initiate 
the formation of pS129- αSyn structures in any of the mDA 
neuronal cultures (Figure 6b, Supporting Information Figure 
S6). To confirm these results with an independent cell line, 
we used the same strategy to target exon 2 of the SNCA gene 
in AST18 iPSCs, which harbour a triplication containing the 
SNCA locus (Devine et al., 2011). We obtained four clonal 
iPSC lines that lacked α- synuclein protein expression based 
on western blotting (Figure 7a). AST18 (SNCATrip) and 
AST18- 7B (SNCAnull) iPSCs were differentiated into mDA 
neurons and treated with α- synuclein PFFs using the same 
conditions for hESC- derived neurons. Upon fixing and im-
munostaining for pS129- αSyn it was observed that SNCATrip 
neurons exhibited numerous pS129- αSyn structures along 
neurites, while these structures were virtually absent in the 
SNCAnull neurons (Figure 7b). Image quantification of the 
pS129- αSyn area demonstrated a significant reduction of 
the Lewy- like structures in SNCAnull neurons (Figure 7c), 
which is in agreement with the observation in hESC- derived 
neurons.
4 |  DISCUSSION
A dopaminergic cell replacement therapy for Parkinson’s is 
rapidly approaching clinical trials (Barker et al., 2017). We 
know from clinical trials with fetal mesencephalic grafts that 
significant dopaminergic re- innervation can be achieved, 
and this is accompanied by significant clinical benefit 
(Lindvall et al., 1990, 1994; Ma et al., 2010). However, the 
cells transplanted into the Parkinson’s striatum are suscep-
tible to synucleinopathy and the formation of Lewy bodies 
(Kordower et al., 2008; Li et al., 2008; Mendez et al., 2008). 
Over time this reduces the clinical benefit of the graft and a 
re- emergence of motor symptoms (Li et al., 2016). The on- 
going synucleinopathy to other parts of the brain, such as the 
cortex, will likely contribute to a worsening of symptoms as 
well. Here, we have engineered human pluripotent stem cells 
with CRISPR/Cas9 nickase technology to reduce or remove 
the SNCA alleles encoding for α- synuclein. Using Cas9n with 
F I G U R E  5  α- Synuclein pre- formed fibrils (PFFs) seeding and the process of phosphorylated Serine 129 α- synuclein (pS129- αSyn) 
quantification. (a) Time line of PFFs seeding and pS129- αSyn quantification during mDA differentiation. (b) WT mDA neurons seeded with PFFs 
for 5 weeks, immunostained with pS129- αSyn (green) and β- III tubulin (red): colour images (left panel) and respective binary images (right panel), 
with partially 2.8× enlarged images and percentage of overlapping pS129- αSyn staining normalized to β- III tubulin immunostaining
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four gRNAs, we were able to successfully remove the first 
coding exon, exon 2, of the human SNCA gene in clinical- 
grade RC17 hESCs to produce a number of SNCA+/− and 
SNCA−/− clonal cell lines, as well as deleting all four alleles 
of SNCA from the α- synuclein triplication iPSC line, AST18. 
All genotypes of cell line efficiently produced mDA neurons 
in a modified floor plate protocol suggesting that removal of 
the α- synuclein protein does not grossly affect the differen-
tiation propensity of pluripotent stem cells into this neuronal 
subtype. More detailed transcriptomic analysis and functional 
studies of dopamine release, for example, will be required to 
determine if more subtle differences exist between wild- type 
human neurons and the ones that lack α- synuclein, especially 
since Snca−/− mice have reduced dopamine content in the 
striatum despite normal numbers of dopaminergic neurons 
in the substantia nigra (Abeliovich et al., 2000; Al- Wandi 
et al., 2010). Analysis of synaptic vesicle mobilisation in ma-
ture mDA neurons will also be important, since mice lacking 
α- synuclein exhibit a deficit in replenishing pools of presyn-
aptic vesicles after depletion in hippocampal neurons (Cabin 
et al., 2002), and this phenotype was also observed in the 
striatum of triple knock- out mice lacking all three synuclein 
genes, Snca, Sncb, Sncg (Anwar et al., 2011). It is interesting 
to note that Snca−/− mice exhibit a degree of resistance to 
F I G U R E  6  pS129- αSyn quantification of SNCA+/−, SNCA−/− or WT mDA neurons seeded with PFFs or monomers. (a) SNCA+/−, SNCA−/− 
and WT mDA neurons seeded with PFFs for 5 weeks, immunostained with pS129- αSyn (green) and β- III tubulin (red): colour images (left panel) 
and respective binary images (right panel). (b) Quantification of overlapping pS129- αSyn immunostaining in PFF and monomer- seeded mDA 
neurons normalized to β- III tubulin immunostaining presented as box plots. (PFF data: SNCA+/+, n = 6, 18 images; SNCA+/−, n = 6, 16 images; 
SNCA−/−, n = 4, 12 images. Monomer data: SNCA+/+, n = 3, 6 images; SNCA+/−, n = 4, 11 images; SNCA−/−, n = 1, 2 images) ****p < 0.0001, 
*p < 0.05: Mann–Whitney U test
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the mitochondrial toxin MPTP (Dauer et al., 2002; Robertson 
et al., 2004), suggesting α- synuclein- null grafts may have 
some protection against environmental toxins. However, 
Snca−/− mice are highly susceptible to neuroinvasive viruses, 
such as West Nile virus, while heterozygous Snca+/− mice do 
not display this phenotype (Beatman et al., 2015).
In agreement with our data, the loss of α- synuclein in 
mice confers complete resistance to experimentally induced 
synucleinopathy (Luk et al., 2012), which is analogous to the 
finding that the endogenous PrP gene is critical to be sus-
ceptible to prion infection (Mallucci et al., 2003). When we 
challenged wild- type, SNCA+/− and SNCA−/− mDA neurons 
with recombinant α- synuclein PFFs, we observed a signifi-
cant number of punctate pS129- αSyn structures in wild- type 
neurons, but very few or none in SNCA+/− and SNCA−/− neu-
rons. Exposing mDA neurons to monomeric α- synuclein 
protein at the same concentration was unable to produce 
pS129- αSyn structures. The lack of pS129- αSyn structures 
in SNCA−/− neurons was expected from the data published in 
rodent neurons and mice (Luk et al., 2012; Volpicelli- Daley 
et al., 2011). However, the significantly reduced pS129- αSyn 
structures in heterozygous SNCA+/− neurons were somewhat 
surprising. This is most likely due to the length of time of the 
assay (5 weeks). Since these neurons express about half the 
level of α- synuclein protein, they would require longer time 
periods to accumulate and mature the pS129- αSyn struc-
tures. This has implications for the longevity of heterozy-
gous SNCA+/− grafts in patients, given the time (>10 years) 
it took wild- type fetal grafts to acquire Lewy pathology and 
begin to fail. Reducing the α- synuclein protein level by 50% 
could significantly increase the functional longevity of the 
graft by slowing and reducing Lewy body burden, while 
avoiding the potential issues of synaptic mobilisation de-
fects or increased susceptibility to neuroinvasive viruses. 
Preclinical testing of SNCA+/− and SNCA−/− mDA cells 
will require an animal model of host- to- graft α- synuclein 
spread. A 6- hydroxydopamine (6- OHDA) lesion model with 
AAV6- human α- synuclein administration in the rat has been 
reported (Kordower et al., 2011). Wild- type rat ventral mes-
encephalon (VM) was used to graft the animals, and between 
2% to 15% of the dopaminergic neurons acquired human α- 
synuclein from the host (Kordower et al., 2011). A mouse 
model of host- to- graft spread has also been reported where 
embryonic mouse VM is transplanted on transgenic mice 
expressing human α- synuclein driven by the mouse SNCA 
promoter (Hansen et al., 2011). Demonstration of disease- 
resistance of human SNCA+/− and SNCA−/− mDA cells in one 
of these models, or similar models, will be required prior to 
clinical translation.
Genome editing with CRISPR/Cas9 technology is 
being applied to address diverse medical problems, includ-
ing cancer, HIV infection, and monogenic diseases (Hsu, 
Lander, & Zhang, 2014; Knott & Doudna, 2018). Genome- 
edited human pluripotent stem cells for clinical trials have 
yet to be reported, but is set to follow the work of genome 
editing of other cell types, such as T cells, for medical ap-
plications. The use of Cas9 nickase technology (Ran et al., 
2013), or next- generation Cas9 enzymes (Kleinstiver 
et al., 2016), have significantly reduced or eliminated off- 
target disruption of the genome and dramatically improved 
the safety profile of genome- engineered cells for clinical 
applications.
Here, we have shown that SNCA+/− and SNCA−/− mDA 
neurons can be generated by a straight- forward genome en-
gineering method via hESCs or iPSCs, and they present a 
F I G U R E  7  pS129- αSyn pathology model is reproducible 
in hiPSCs. (a) Western blotting of triplication SNCA AST18 iPSC 
clones targeted for deletion of exon 2 of SNCA gene. (b) SNCATrip 
and SNCAnull (7B clone) mDA neurons seeded with α- Syn PFFs or 
monomers, immunostained with pS129- αSyn (green) and β- III tubulin 
(red). Three representative images are shown for each condition. (c) 
Quantification of pS129- αSyn immunostaining in β- III tubulin- positive 
domain for PFF and monomer- seeded mDA neurons presented as box 
plots. **p < 0.01: Mann–Whitney U test
14 |   CHEN Et al.
significant opportunity to produce next- generation cell prod-
ucts that exhibit resistance to Parkinson’s pathology.
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